A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)

• Status: Completed
• Trial end date: 2014-02-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a phase 2 study of the HSP90 inhibitor, STA-9090 (ganetespib) in subjects with stage IIIB or IV non-small cell lung cancer (NSCLC).

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Synta Pharmaceuticals Corp.

Criteria

Inclusion Criteria:

• Pathologically confirmed diagnosis of Stage IIIB (with pleural effusion) or Stage IV NSCLC with measurable disease by RECIST and evidence of progression

• Availability of tissue for analysis

• ECOG Performance Status 0 or 1

• Adequate organ function as defined in the protocol.

• Must be at least 18 years old and able and willing to sign a written informed consent document

Exclusion Criteria:

• Poor venous access requiring an indwelling catheter for study drug administration

• Women who are pregnant or lactating

• Ventricular ejection fraction < or = to 55% at baseline

• Any uncontrolled intercurrent illness